tiprankstipranks
Trending News
More News >
China Shineway Pharmaceutical Group Limited (HK:2877)
:2877
Hong Kong Market

China Shineway Pharmaceutical Group Limited (2877) Financial Statements

Compare
0 Followers

China Shineway Pharmaceutical Group Limited Financial Overview

China Shineway Pharmaceutical Group Limited's market cap is currently HK$5.92B. The company's EPS TTM is HK$1.205; its P/E ratio is 6.50; and it has a dividend yield of 9.82%. China Shineway Pharmaceutical Group Limited is scheduled to report earnings on April 1, 2025, and the estimated EPS forecast is HK$―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue¥ 3.78B¥ 4.52B¥ 3.95B¥ 3.22B¥ 2.66B
Gross Profit¥ 2.83B¥ 3.39B¥ 2.94B¥ 2.41B¥ 1.99B
Operating Income¥ 842.60M¥ 975.53M¥ 713.58M¥ 534.37M¥ 422.40M
EBITDA¥ 1.00B¥ 1.42B¥ 1.10B¥ 903.74M¥ 620.04M
Net Income¥ 840.05M¥ 969.51M¥ 722.77M¥ 556.67M¥ 295.03M
Balance Sheet
Cash & Short-Term Investments¥ 6.49B¥ 5.91B¥ 5.05B¥ 4.21B¥ 3.95B
Total Assets¥ 10.04B¥ 9.57B¥ 8.23B¥ 7.20B¥ 7.21B
Total Debt¥ 346.53M¥ 301.33M¥ 7.44M¥ 14.91M¥ 392.14M
Net Debt¥ -5.79B¥ -5.59B¥ -5.02B¥ -4.19B¥ -3.55B
Total Liabilities¥ 2.57B¥ 2.54B¥ 1.85B¥ 1.30B¥ 1.42B
Stockholders' Equity¥ 7.47B¥ 7.03B¥ 6.38B¥ 5.90B¥ 5.79B
Cash Flow
Free Cash Flow¥ 823.02M¥ 788.31M¥ 980.21M¥ 609.52M¥ 572.54M
Operating Cash Flow¥ 963.13M¥ 932.63M¥ 1.11B¥ 703.15M¥ 638.57M
Investing Cash Flow¥ -272.11M¥ -49.54M¥ -45.42M¥ 395.01M¥ -305.59M
Financing Cash Flow¥ -392.48M¥ -26.74M¥ -250.04M¥ -828.93M¥ -329.79M
Currency in CNY

China Shineway Pharmaceutical Group Limited Earnings and Revenue History

China Shineway Pharmaceutical Group Limited Debt to Assets

China Shineway Pharmaceutical Group Limited Cash Flow

China Shineway Pharmaceutical Group Limited Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis